GlassScriptPhysician profile
Deborah A Jacoby
NPI 1255515847
$7,022.93
in general payments reported to CMS, 2019-2025
40 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,179 · 2022: $1,395 · 2023: $1,712 · 2024: $1,379 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,855 · Consulting Fee: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,854.52 |
| Consulting Fee | $595.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $891.76 | 2021-2025 | Strensiq |
| Corcept Therapeutics | $855.57 | 2021-2025 | Korlym |
| Lilly USA, LLC | $796.01 | 2021-2025 | Jardiance, Mounjaro, Baqsimi |
| Abbvie INC. | $517.97 | 2021-2025 | |
| Amgen INC. | $437.13 | 2021-2025 | Tepezza, Evenity, Prolia |
| Dexcom, INC. | $422.96 | 2021-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $391.73 | 2021-2024 | Omnipod |
| Novo Nordisk INC | $384.21 | 2021-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $331.72 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.08 | 2021-2025 | Jardiance |
| Beta Bionics, INC. | $152.65 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Abbott Laboratories | $146.36 | 2021-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $136.56 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $128.44 | 2021-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $118.21 | 2021-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $102.61 | 2024-2025 | Isturisa, Signifor Lar |
| Mannkind Corporation | $100.84 | 2021-2025 | Afrezza |
| Radius Health, INC. | $97.02 | 2024-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $68.58 | 2022-2025 | Gvoke Hypopen |
| Becton, Dickinson and Company | $62.62 | 2022 | |
| Sequel Med Tech, LLC | $56.58 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $56.17 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $54.90 | 2021-2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $47.50 | 2024-2025 | Yorvipath |
| Horizon Therapeutics Plc | $44.84 | 2022-2023 | Tepezza |
| Zealand Pharma US, INC. | $44.04 | 2021 | |
| Rgh Enterprises LLC | $35.56 | 2025 | |
| Acella Pharmaceuticals, LLC | $34.27 | 2023-2025 | NP Thyroid 60 |
| Ibsa Pharma INC. | $30.00 | 2025 | Flector, Tirosint, Licart |
| Embecta Corp. | $27.90 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Astellas Pharma US INC | $22.51 | 2024 | Veozah |
| Amryt Pharma Holdings LTD | $19.73 | 2023 | Mycapssa |
| Cequr Corporation | $19.31 | 2024 | Cequr Simplicity |
| Alvogen INC | $18.55 | 2022 | |
| Smith+Nephew, INC. | $18.16 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.12 | 2023 | |
| Intuity Medical INC | $16.72 | 2022 | |
| Grt US Holding, INC. | $15.16 | 2021 | |
| Esperion Therapeutics, INC. | $15.04 | 2022 | |
| Amarin Pharma, INC. | $14.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Jacoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.